// Company Overview //
| Stock Name | 心泰医疗 |
|---|---|
| Stock Code | 02291 |
| Company Full Name | 心泰医疗 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事研發、生產及商業化心臟病介入醫療器械。 |
| Listing Date | 2022-11-08 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | No data |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市松江區莘磚公路258號41幢1樓、5樓 |
| Business Address (Hong Kong) | No data |
| Place of Incorporation | No data |
| Listing Method | No data |
| Listing Board | Main Board |
| Website | http://www.scientechmed.com/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
// Offering Information //
| Offering Mechanism | 未知 |
|---|---|
| Clawback Tiers | No data |
| Prospectus Date | 2022-10-27 |
| Offer Price | HK$ 29.15 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 1,000 shares |
| Entry Threshold | HK$ 29,150 |
| Par Value | No data |
| Global Offering Shares | — |
| HK Public Offering Shares | — (0%) |
| International Placing Shares | — (0%) |
| Offer Ratio | No data |
| Total Shares Post-IPO | No data |
| Total Global Offering Size | HK$ — |
| Public Offering Size | HK$ — (0%) |
| Oversubscription Multiple | —x |
| Valid Applications | — |
| Accepted Applications | — |
| Reallocation | No |
| Total Funds Raised | HK$ 65,470,900 |
| Greenshoe (Over-allotment Option) | No data |
// Valuation & Financials //
| Market Cap (at Offer Price) | HK$ 0 |
|---|---|
| Pre-IPO Valuation (Last Round) | No data |
| P/E Ratio | 140.69 |
| Profit/Loss Status | No data |
| Period-End Cash Balance | No data |
| Listing Expenses | ~HK$ 88,300,000 |
| Listing Expenses / Funds Raised | No data |
| Total Pre-IPO Investment | No data |
// First Day Performance
| First Day Close | Loading... |
|---|---|
| First Day Open | HK$ 29.8 |
| First Day Change | -62.09% |
| First Day Volume | 3807000.0 |
| First Day Turnover | 111634000.0 |
// Price Chart //
Loading...
// Use of Proceeds
| Use of Proceeds | 1、約50.7%（或約287.6百萬港元）將用于為未來五年內的研發活動提供資金； 2、約24.3%（或約137.9百萬港元）將用于未來五年內的銷售及營銷活動； 3、約5.0%（或約28.4百萬港元）將用于在未來五年內提升產能及加強制造能力； 4、約10.0%（或約56.7百萬港元）將用于為未來五年內潛在的戰略投資及收購提供資金，以補充和擴大我們的產品組合及技術； 5、約10.0%（或約56.7百萬港元）將用于營運資金及一般公司用途。 |
|---|
// Underwriting Syndicate //
独家保荐人 (1)
中国国际金融香港证券有限公司
整体协调人 (1)
中国国际金融香港证券有限公司
联席账簿管理人 (5)
中国国际金融香港证券有限公司
中信里昂证券有限公司
中国银河国际证券（香港）有限公司
华泰金融控股（香港）有限公司
华盛资本证券有限公司
联席牵头经办人 (5)
中国国际金融香港证券有限公司
中信里昂证券有限公司
中国银河国际证券（香港）有限公司
华泰金融控股（香港）有限公司
华盛资本证券有限公司
// Cornerstone Investors //
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Harvest International Premium Value (Secondary Market) Fund SPC | 78,471,800 HKD | — | 11.99% | — | 6 months | 2023-05-08 |
| 2 | 九州通国际集团有限公司 | 39,235,900 HKD | — | 5.99% | — | 6 months | 2023-05-08 |
| 3 | 上海临港经济发展集团投资管理有限公司 | 76,897,700 HKD | — | 11.75% | — | 6 months | 2023-05-08 |
// Directors & Management //
| Chairman | 陳娟 |
|---|---|
| Company Secretary | 秦學;楊麗珊 |
No director data available.
// Major Shareholders //
| Major Shareholders & Holdings | 樂普(北京)醫療器械股份有限公司(80.75%) |
|---|
// Allotment Benchmarks //
Pool A (Small Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 1,000 | 483 | 483 | 1.00 |
| 2,000 | 55 | 55 | 1.80 |
| 3,000 | 37 | 37 | 2.54 |
| 4,000 | 13 | 13 | 3.00 |
| 5,000 | 19 | 19 | 3.21 |
| 6,000 | 9 | 5 | 3.56 |
| 7,000 | 3 | 2 | 3.67 |
| 8,000 | 4 | 3 | 3.75 |
| 9,000 | 1 | 1 | 4.00 |
| 10,000 | 20 | 20 | 4.20 |
| 20,000 | 8 | 8 | 8.00 |
| 30,000 | 3 | 3 | 11.67 |
| 50,000 | 4 | 4 | 18.00 |
| 100,000 | 1 | 1 | 30.00 |
Pool B (Large Subscriptions)
| Shares Applied | Applicants | Allottees | Expected Lots |
|---|---|---|---|
| 200,000 | 2 | 2 | 74.50 |
| 300,000 | 5 | 5 | 111.39 |
| 1,123,000 | 1 | 1 | 416.97 |
Allotment Benchmarks
